(Q64122664)
Statements
An Open-label, Phase 1 Trial for Safety and Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell("HYNR-CS-Allo Inj") Treatment in Amyotrophic Lateral Sclerosis(ALS) (English)
0 references
1 February 2017
0 references
25 March 2019
0 references
6
0 references
25 year
0 references
80 year
0 references